Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H14N2O.C4H4O4 |
| Molecular Weight | 330.3352 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.NC1=C2C=CC=CC2=NC3=C1C(O)CCC3
InChI
InChIKey=NEEKVKZFYBQFGT-WLHGVMLRSA-N
InChI=1S/C13H14N2O.C4H4O4/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13;5-3(6)1-2-4(7)8/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1+
Velnacrine (9-amino-1,2,3,4-tetrahydroacridin-1-ol) is an inhibitor of acetylcholinesterase. It was studied for the treatment of Alzheimer's disease however development was discontinued. There has been no research into the use of velnacrine as a cognitive enhancer in the treatment of Alzheimer's disease since 1994. The FDA peripheral and CNS drug advisory board voted unanimously against recommending approval. This review shows the toxic nature of velnacrine, and provides no evidence of efficacy.
Originator
Approval Year
Sample Use Guides
Velnacrine for the treatment of Alzheimer's disease (a double-blind, placebo-controlled trials): 10, 25, 50 and 75 mg t.i.d. The 225 mg/day dose appears to be safe for use in multicenter outpatient trials of velnacrine efficacy in Alzheimer's disease.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
333408-28-9
Created by
admin on Sat Dec 16 10:19:39 GMT 2023 , Edited by admin on Sat Dec 16 10:19:39 GMT 2023
|
PRIMARY | |||
|
6364836
Created by
admin on Sat Dec 16 10:19:39 GMT 2023 , Edited by admin on Sat Dec 16 10:19:39 GMT 2023
|
PRIMARY | |||
|
Z2589Z87DE
Created by
admin on Sat Dec 16 10:19:39 GMT 2023 , Edited by admin on Sat Dec 16 10:19:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
